Published : Jun-2019
No. of Pages : 147
1.1 List of Tables
1.2 List of Figures
2 B-Cell NHL: Executive Summary
2.1 The B-Cell NHL Market Is Expected to Grow to $9.2B in 2027
2.2 Combinations with Rituxan and Label Expansions Across B-Cell NHL Will Continue to Be the Prominent Strategies Utilized by Developers
2.3 Moderate Level of Overall Unmet Need, but Opportunities Remain in Specific Settings
2.4 Large Pipeline Composed of Therapies with Relatively High Potential
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology
4.1.1 FL
4.1.2 MZL
4.1.3 DLBCL
4.1.4 MCL
4.2 Pathophysiology
4.2.1 FL
4.2.2 MZL
4.2.3 DLBCL
4.2.4 MCL
4.3 Staging
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for B-Cell NHL (2017-2027)
5.5.1 Diagnosed Incident Cases of B-Cell NHL
5.5.2 Age-Specific Diagnosed Incident Cases of B-Cell NHL
5.5.3 Sex-Specific Diagnosed Incident Cases of B-Cell NHL
5.5.4 Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL
5.5.5 Diagnosed Incident Cases of DLBCL by Cancer Staging
5.5.6 Diagnosed Incident Cases of FL by Cancer Staging
5.5.7 Diagnosed Incident Cases of MZL by Cancer Staging
5.5.8 Diagnosed Incident Cases of MCL by Cancer Staging
5.5.9 Diagnosed Incident Cases of FL by Grade
5.5.10 Diagnosed Prevalent Cases of B-Cell NHL
5.5.11 Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Current Treatment Options
6.1 Overview
6.1.1 Agents Used Across the Four Subtypes and Across Lines of Therapy
6.1.2 Rituxan Hycela, Rituximab Biosimilars, and Gazyva
6.1.3 Small Molecule Inhibitors in MCL, FL, and MZL
6.1.4 CAR-T Therapy in DLBCL
7 Unmet Needs and Opportunity Assessment
7.1 Overview
7.2 Predictive and Prognostic Molecular Biomarkers
7.2.1 GCB and Non-GCB Histology in DLBCL
7.2.2 Patients Who Are Not Cured with 1L R-CHOP in DLBCL
7.2.3 The POD24 Group in FL
7.2.4 DGM1-Positive Patients in DLBCL
7.3 Improvement of Cure Rate and Better Therapies for DLBCL Patients Who Are Not Cured by 1L R-CHOP
7.4 Further Options in FL for Various Patient Subsets
7.5 Patients Refractory to/Relapsed after Treatment with Imbruvica in MCL
7.6 Clinical Research in MZL
8 R&D Strategies
8.1 Overview
8.1.1 Label Expansions to Additional NHL Subtypes and Lines of Therapy
8.1.2 Novel Mechanisms of Action
8.1.3 Exploration of Novel Combinations With and Without Rituxan
8.2 Clinical Trials Design
8.2.1 Ongoing Late-Stage Trials of Marketed and Pipeline Drugs
8.2.2 PFS is the Most Common Clinical Trial Endpoint
8.2.3 Comparator Arms
9 Pipeline Assessment
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline and Marketed Drugs
10.1.1 iNHL
10.1.2 DLBCL
10.1.3 MCL
10.2 Commercial Benchmark of Key Pipeline Drugs
10.2.1 iNHL
10.2.2 DLBCL
10.2.3 MCL
10.3 Competitive Assessment
10.4 Top-Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.3.1 Forecasting Methodology
11.3.2 Diagnosed Patients
11.3.3 Percent Drug-Treated Patients
11.3.4 Drugs Included in Each Therapeutic Class
11.3.5 Launch and Patent Expiry Dates
11.3.6 General Pricing Assumptions
11.3.7 Individual Drug Assumptions
11.3.8 Generic Erosion
11.3.9 Pricing of Pipeline Agents
11.4 Primary Research - KOLs Interviewed for This Report
11.5 Primary Research - Prescriber Survey
11.6 About the Authors
11.6.1 Analyst
11.6.2 Therapy Area Directors
11.6.3 Epidemiologist
11.6.4 Managing Epidemiologist
11.6.5 Global Director of Therapy Analysis and Epidemiology
11.6.6 Global Head and EVP of Healthcare Operations and Strategy
11.7 About GlobalData
11.8 Contact Us
11.9 Disclaimer
List of Tables
Table 1: B-Cell NHL: Key Metrics in the 7MM
Table 2: Molecular Characteristics of NHL (2008 WHO Classification)
Table 3: The Ann Arbor Staging System and the Cotswold Modifications for NHL
Table 4: B-Cell NHL Cancer Stages
Table 5: Risk Factors and Comorbidities for NHL
Table 6: Treatment Guidelines for B-Cell NHL
Table 7: Leading Treatments for B-Cell NHL
Table 8: Ongoing Phase III/Pivotal Phase II Trials in B-cell NHL of Pipeline Drugs
Table 9: Ongoing Phase III Trials in B-cell NHL of Marketed Drugs
Table 10: Comparison of Therapeutic Classes in Development for NHL, 2018-2027
Table 11: Clinical Benchmark of Key Pipeline and Marketed Drugs - iNHL
Table 12: Clinical Benchmark of Key Pipeline and Marketed Drugs - DLBCL
Table 13: Clinical Benchmark of Key Pipeline and Marketed Drugs - MCL
Table 14: Commercial Benchmark of Key Pipeline and Marketed Drugs - iNHL
Table 15: Commercial Benchmark of Key Pipeline and Marketed Drugs - DLBCL
Table 16: Commercial Benchmark of Key Pipeline and Marketed Drugs - MCL
Table 17: Key Events Impacting Sales for B-cell NHL, 2017-2027
Table 18: B-cell NHL Market - Global Drivers and Barriers, 2017-2027
Table 19: Key Historical and Projected Launch Dates for B-cell NHL
Table 20: Key Historical and Projected Patent Expiry Dates for B-cell NHL
Table 21: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Region for B-Cell NHL in 2017 and 2027
Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs for iNHL (FL and MZL) Benchmarked Against the SOC, Rituxan (+/- chemotherapy)
Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs for DLBCL Benchmarked Against the SOC, Rituxan (+/- chemotherapy)
Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs for MCL Benchmarked Against the SOC, Rituxan (+/- chemotherapy)
Figure 5: 7MM, Age-Standardized Diagnosed Incidence of B-Cell NHL, Ages ?18 Years, 2017
Figure 6: 7MM, Age-Standardized Diagnosed Prevalence of B-Cell NHL, Ages ?18 Years, 2017
Figure 7: Sources Used for Diagnosed Incident Cases of B-Cell NHL
Figure 8: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL
Figure 9: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL by Cancer Staging
Figure 10: Sources Used for Diagnosed Incident Cases of FL by Grade
Figure 11: Sources Used for Diagnosed Prevalent Cases of B-Cell NHL
Figure 12: Sources Used for Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL
Figure 13: 7MM, Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages ?18 Years, 2017
Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, 2017
Figure 15: 7MM, Sex-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages ?18 Years, 2017
Figure 16: 7MM, Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages ?18 Years, 2017
Figure 17: 7MM, Diagnosed Incident Cases of DLBCL by Cancer Stage, Men and Women, Ages ?18 Years, 2017
Figure 18: 7MM, Diagnosed Incident Cases of FL by Cancer Stage, Men and Women, Ages ?18 Years, 2017
Figure 19: 7MM, Diagnosed Incident Cases of MZL by Cancer Stage, Men and Women, Ages ?18 Years, 2017
Figure 20: 7MM, Diagnosed Incident Cases of MCL by Cancer Stage, Men and Women, Ages ?18 Years, 2017
Figure 21: 7MM, Diagnosed Incident Cases of FL by Grade, Men and Women, Ages ?18 Years, 2017
Figure 22: 7MM, Diagnosed Prevalent Cases of B-Cell NHL, Men and Women, ?18 Years, 2017
Figure 23: 7MM, Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages ?18 Years, 2017
Figure 24: Unmet Needs and Opportunities in B-cell NHL
Figure 25: Overview of the Development Pipeline in iNHL (FL and MZL)
Figure 26: Overview of the Development Pipeline in DLBCL
Figure 27: Overview of the Development Pipeline in MCL
Figure 28: Key Phase II/III Trials for the Pipeline Agents in the 7MM During the Forecast Period
Figure 29: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, iNHL
Figure 30: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Indolent DLBCL
Figure 31: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Indolent MCL
Figure 32: Global (7MM) Sales Forecast by Region for B-cell NHL in 2017 and 2027
Figure 33: Global (7MM) Sales Forecast by Class for Disease B-cell NHL in 2017 and 2027
